Aerovate Therapeutics (NASDAQ:AVTE) & AEON Biopharma (NASDAQ:AEON) Head to Head Survey

Aerovate Therapeutics (NASDAQ:AVTE) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Aerovate Therapeutics and AEON Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0	0	0	0	0.00
AEON Biopharma	0	1	1	1	3.00

Volatility and Risk

Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Institutional and Insider Ownership

22.8% of AEON Biopharma shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by insiders. Comparatively, 0.9% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Aerovate Therapeutics and AEON Biopharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52 million	($1.70)	-10.52
AEON Biopharma	N/A	N/A	-$36.63 million	($2.43)	-0.35

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aerovate Therapeutics and AEON Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
AEON Biopharma	N/A	N/A	-994.63%

Summary

AEON Biopharma beats Aerovate Therapeutics on 7 of the 11 factors compared between the two stocks.

About Aerovate Therapeutics

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.